Proteomic Profiles in Trabeculectomy Patients

NCT ID: NCT01841580

Last Updated: 2018-10-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-11-30

Study Completion Date

2018-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Approximately 70 million people world-wide are affected with glaucoma, of whom 6.7 million have bilateral blindness.5 Elevated intro-ocular pressure is the major modifiable risk factor in glaucoma, and reducing intraocular pressure to a consistently low level can delay disease progression and therefore, blindness.6 Topical intraocular pressure -lowering medication remains the first-line treatment for glaucoma, with surgical intervention playing a secondary role in cases suboptimally controlled with medication alone.

In this study, we plan to assess the change in tear proteins in trabeculectomy patients before and after operations. It is hoped that this study could help us gain more understanding of the possible mechanism accounting for the development of dry eye disease in glaucoma patients, which could help us develop better screening modalities and therapeutic agents for glaucoma patients at risk to prevent the development of dry eye disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objectives and Purpose

There are two primary aims in this study:

1. To assess changes in the tear proteomic profiles in pre-trabeculectomy and post-trabeculectomy patients
2. To assess the changes in clinical signs of the eye and tear film as well as dry eye symptoms.

Study Material Human Tears will be collected from patients in SNEC clinic

Study Design:

120 patients will be recruited for this study (details as described below). Schirmers I test, Tear Osmolarity, Tear Break Up Time (TBUT), Anterior segment optical coherence tomography (ASOCT) and Impression cytology will be done during the study visits. Subjective symptom and severity of dry eye disease will be assessed through Visual Analog Scale (VAS).

No. of visits:

There will be 4 visits in this study. Visit 1: Pre-trabeculectomy operation Visit 2: 6 month after trabeculectomy surgery Visit 3: 1 year after trabeculectomy surgery Visit 4: 3 years after trabeculectomy surgery

Selection and Withdrawal of Subjects Recruitment Criteria

1. 120 patients will be recruited from glaucoma clinics in SNEC
2. Patients age ≥ 21 years old
3. Patients who require trabeculectomy operation

Treatment of subjects

Study Procedures:

1. Fluorescein staining will be used to visualize patient eyes.
2. Schirmer's test will be used to measure the amount of tear production

1. A small strip of filter paper will be inserted inside the lower eyelid
2. A topical aneasthetic is placed into the eye before the filter paper to prevent tearing due to the irritation from the paper
3. The eyes are closed for 5 minutes.
4. The paper is then removed and the amount of moisture is measured
3. Impression cytology will be performed to collect the superficial conjunctival cells for analysis

1. While the eye is still anaesthetized from Schirmer's test, one end of a filter paper will be impressed upon the temporal conjunctiva whilst the other hand is grasped in place with a blunt smooth edged forceps.
2. The filter paper is removed from the conjunctiva with a peeling motion after 2-3 seconds.
3. The paper is placed into an eppendorf tube for future analysis.
4. Tear osmolarity, Tear Break Up Time (TBUT) will be measured in all patients

a) Tear osmolarity will be measured using the osmolarity chip, 3 chips per eye
5. Anterior segment optical coherence tomography will be performed to assess the tear meniscus and image for any conjunctivochalasis

a) The patient will be asked to look at a target in the instrument while blinking normally. The instrument will scan the lower eyelid margin for imaging of the tear meniscus and conjunctivochalasis
6. Symptoms and severity of dry eye disease will be assessed through the Visual Analog Scale (VAS) system

Assessment of efficacy Outcome Measures

1. Symptoms and severity of dry eye disease will be quantified based on the Visual Analog Scale (VAS)11
2. Amount of moisture of the filter paper will be measured in Schirmer's test
3. Clinical assessment of dry eye disease through Tear break up time (TBUT) and Tear Osmolarity measurements
4. Tear meniscus height and area in the images obtained with optical coherence tomography

Target sample size 120 subjects will be enrolled in the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 120 patients will be recruited from glaucoma clinics in SNEC
2. Patients age ≥ 21 years old
3. Patients who require trabeculectomy operation
Minimum Eligible Age

21 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Singapore National Eye Centre

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Louis Tong

Clinician-Scientist, Senior Consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Louis Tong, PhD

Role: PRINCIPAL_INVESTIGATOR

Singapore National Eye Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Singapore National Eye Centre/ Singapore Eye Research Institute

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013/020/A

Identifier Type: OTHER

Identifier Source: secondary_id

R980/89/2012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Advanced Glaucoma Progression Study
NCT01742819 ACTIVE_NOT_RECRUITING